药捷安康-B(02617):替恩戈替尼联用康方生物开坦尼®(卡度尼利,PD-1/CTLA-4)╱ 依达方®(依沃西,PD-1/VEGF)的II期临床试验完成首例患者给药

智通财经
Sep 04

智通财经APP讯,药捷安康-B(02617)发布公告,公司核心产品替恩戈替尼(Tinengotinib, TT-00420)分别联用康方生物科技(开曼)有限公司开坦尼®(卡度尼利,PD-1/CTLA-4)╱依达方®(依沃西,PD-1/VEGF)的治疗晚期肝细胞癌(hepatocellular carcinoma, HCC)的开放性、多中心II期临床研究,于近日完成首例患者给药。

本试验为在中国开展的一项评价开坦尼®(卡度尼利,PD-1/CTLA-4)╱依达方®(依沃西,PD-1/VEGF)联合替恩戈替尼片治疗晚期肝细胞癌疗效和安全性的开放性、多中心、II期临床研究,试验的主要目标为评估开坦尼®(卡度尼利,PD-1/CTLA 4)╱依达方®(依沃西,PD-1/VEGF)分别联合替恩戈替尼片或替恩戈替尼单药治疗晚期肝细胞癌的安全性和有效性。该试验的主要目标人群为既往未接受过针对肝细胞癌的全身抗肿瘤治疗或既往标准治疗失败后的晚期肝细胞癌患者。

药捷安康已与康方生物订立合作协议,双方共同针对肝细胞癌领域开展临床联合用药开发。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10